Mastodynia elimination at hormonal treatment of patients with uterine myoma


  • А. Л. Тихомиров Moscow State Medico-Stomatological University, Russian Federation
  • А. А. Леденкова Moscow State University of Medicine and Dentistry named after A.I. Evdokimov, Russian Federation



uterine fi broids, benign mammary dysplasia, Agnus castus, Mastodynon


High frequency (at 54,2%) of combination of uterine fi broids and benign mammary dysplasia may be due to their common etiology and pathogenesis.

A large amount of literature data that based on clinical studies show the eff ectiveness of herbal and homeopathic medicines in treatment of mastitis, that is especially important in their nomination in patients with uterine myoma.

Agnus castus is the most studied among the medicinal plants that have affi nity for the neuroendocrine system of a human and preparations on the basis of which (including Mastodynon) is eff ectively used for the treatment of latent hyperprolactinemia and mastodynia, premenstrual and menopausal syndromes.

Studies have shown that Mastodynon helps to reduce the pain associated with mastitis and premenstrual syndrome, and also reduces the swelling of the glandular component, so it can be recommended for the treatment of diff use form of mammary dysplasia. Mastodynon is also possible to use during the course of hormonal therapy in patients with uterine myoma to ensure maximum safety and comfort for the patient treatment process

Author Biographies

А. Л. Тихомиров, Moscow State Medico-Stomatological University

MD, professor of the Obstetrics and Gynecology Department

А. А. Леденкова, Moscow State University of Medicine and Dentistry named after A.I. Evdokimov

Obstetrics and Gynecology Department


  1. Burdina L.M., Burdina I.I. «Mastodynon H and its role in the treatment of benign breast diseases.» Mammalogy, 4(1998):28-34, 45-57.
  2. Voznyuk N.E., Starikova L.G., Khoruzhaya V.A. «Prolactinoma and hyperprolactinemia.» Herald of new medical technologies, VII(2) (2000):97-100.
  3. Gurkin Y.A. «The modern view on the treatment of girls and young women suff ering from breast pathology.» Journal of Obstetrics and Women’s Diseases (Saint-Petersburg), 3(2000) XLIX.
  4. Gorjacheva L.A., Pinhosevich E.G. «Herbal medicine for diseases of the breast.» M (1996).
  5. Dedov I.I., Semicheva T.V., Peterkova V.A. «Sexual development of children: norm and pathology.» M .: «COLOR It Studio»(2002):1-232.
  6. Kantsaliev A.L. «Effi cacy of Mastodynon H and Vetoron in treatment regimens for dyshormonal breast pathology.» Mammalogy, 4(1998):35-39.
  7. Levenets S.O., Verhoshanova A.G., Perevozchikov V.V. «The level of prolactin and its correction in girls with premature telarhe.» Women Health, 1(29) (2007):134-139.
  8. Mustafi n C.N. «Diagnostics and treatment of diff use mastopathy.» Mammalogy (2009):20-23.
  9. Naumkina N.G. «New approaches to diagnostics and treatment of fi brocystic breast disease: Thesis for PhD» M. (1999):3-15.
  10. Pinhosevich E.G., Burdina L.M., Gorjacheva L.A. et al. «Herbal medicine for breast diseases, clinical and radiological evaluation of treatment.» Mammalogy, 4(1996):15-21.
  11. Prilepskaya V.N., Tagiyeva T.T. «Fibrocystic disease of the breast: the possibility of non-hormonal therapy.» M.: Medline Express, 5(2008):10-17.
  12. Rozhkova N.I., Meskich E.V. «Evaluating the eff ectiveness of herbal medicine with Mastodynon and gelarium in patients with diff use forms of mastitis.» Tumors of the Female Reproductive System, 4(2008):1-2.
  13. Semiglazova V.F. «Mastopathy.» St.-Petersburg.: Kare (2000):109 p.
  14. Serov V.N., Prilepskaya V.N., Ovsyannikova T.V. «Gynecological Endocrinology.» M.: MEDpress-inform (2004):528 p.
  15. Cavaco B., Leite V., Santos M.A. et al. «Some forms of big big prolactin behave as a complex of monomeric prolactin with an immunoglobulin G in patients with macroprolactinemia or prolactinoma.» J. Clin. Endocrinol. Metab, 80(1995):2342-2346.
  16. Cardiff R.D., Wellings S.R. «The comparative patology of human and mouse mammary glands.» J. Mammary Gland Biol. Neoplasia, 4(1999):105-122, 123.
  17. Gruber C.J., Walter Tschugguel, Schneeberger C., Johannes C. Huber. Production and Action of Estrogens.» New Engl. J. Med., 346(5) (2002):340- 352,145.
  18. Kaplowitz P.B., Oberfi eld S.E. «Reexamination of the age limit for defi ning when puberty is precocious in girls in the United States: implications for evaluation and treatment. Drug and Therapeutics and Executive Committees of the Lawson Wilkins Pediatric Endocrine Society.» Pediatrics, 104(4 Pt 1) (1999):936-941.
  19. Pediatric Endocrinology and Growth J.K.H. Wales et al. 2nd edition (2003):41-85.
  20. Halaska M., Beles P., Gorkow C., Sieder C. «Treatment of cyclical maslalgia with a solution containing an extract of Vitex agnus castus: Recent results of a placebo–controlled double-blind study.» The Breast, 8(1999):175-181.
  21. Wuttke W., Splitt G., Gorkow C., Sieder C. «Behandlung zyklusabhangiger Brustschmerzen mit einem Agnus castushaltigen Arzneimittel. Ergebnisse einer randomisierten, placebokontrollierten Doppelblindstudie.» GebFra, 57(1997):569-574.
  22. AACE Menopause Guidelines Revision Task Force. «American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of menopause.» Endocr. Pract, 12(2006):315-337.
  23. Ghent W.R., Eskin B.A., Low D.A., Hill L.P. «Iodine replacement in fi brocystic disease of the breast.» Can. J. Surg., 36(1993):453-460;
  24. Kaunitz A.M. «Oral contraceptive health benefi ts: perception versus reality.» Contraception,. Vol.59 Suppl.1) (1999):29-33;
  25. Schweppe K.W. «The signifi cance ofgestagens in treatment ofmastopathy.» Zentralbl. Gynakol, 119(Suppl. 2) (1997):54-89, 58;
  26. von Fallois J., Etterli-Billenkamp U., Schindler E.M., Schindler A.E. «Danazol for treatment of fi brocystic mastopathy.» Zentralbl. Gynakol, 117(1995):457-465.
  27. Brickell C.(ed). London: Dorling Kindersley (1989).
  28. Brugisser R., Burkard W., Simmen U., Schaff ner W. Phytotherapie, 20:3(1999):154-158.
  29. Christoff el V., Spengler B., Abel G. et al. «Proceedings of the 6th Annual Symposium on complementary.» Health Care. UK., 199.
  30. Du Mee V.A.C. Aust. J. Med. Herbalism, 5(1993): 63-65. Phytotherapie (Munchen) (1999).
  31. Hoberg E. «Swiss Federal Institute of Technology.» Zurich (1999).
  32. Kilicdag E.B., Tarim E., Bagis T. et al. Int. J. Gyn. Obstet, 85(2004):292-293.
  33. Merz P.G., Gorkow C., Schrodter A. et al. Exp. Clin. Endocr. Diabet, 104(1996):447-453.
  34. Pravidel. Novartis Pfarma GmbH Germany (2004).
  35. Wuttke W., Gorkow Ch., Jarry H. Darmstadt: Steinkopff Verlag (1995):81-91.
  36. Sliulz G., Speiser P., Schultz A.M. et al. «Agnus-castus extracts inhibit prolactin secretion of rat pituitary cells.» Horm. Metabol. Res., 25(1993):243-255.
  37. Spengler В., Schmidt J., Porzel A., Christoff el V. «Isolation and characterization of cyclic diterpenes from BNO 1095 (Vitex agnus castus).» In preparation (1999).
  38. Wuttke W., Gorkow C., Jarry H. «Dopaminergic compounds in Vitex agnus castus.» Loew D., Rietbrock N. (Hrsg). Phytopharmaka in forschung und klinischer Anwendung.» Darmstadt: Steinkopff (1995):81-91.
  39. Atmaca M. Kumru, Tezcan S.E. «Fluoxetine Versus Vitex agnus kastus extrakt in the treatment of premenstrual disorder.» Hum. Psychopharmacol, 18:3(2003):191-195.
  40. Breckwoldt M. «Endocrinology and Therapy of breast diseas.» Zentral BL. Gynakol, 112(1990):1097-1099.
  41. Berger D. «Vitex agnus kastus: Unbeden Klichkeit and Wirksamkeit beim praemenstruallen Syndrom, Wirkprinzipien und Wirkmechanismen eines neuetwickelten Extraktes: Dissertation.» Phit-Naturwissenserliebe Fakultat.Besel (1998):Р. 220.
  42. Castillo E., Garibay M., Mirabent F. «Eff ect of alfa dihydroergocriptine in patients with fi brocistiс breast disease.» Gynecol. Obstet. Mex., 74(2006):580-584.
  43. Daniele C., Thompson Coon J. Piuler M.H., Ernst E. «Vitex agnus kastus a systematic review of adverse events.» Drug. Saf, 28(2005):319-332.
  44. Hoberg E., Sticher O., Orjala J.E., Meier B. «Diterpene aus Fgni-casti fructus und ihre Analytik.» Ztsehr. Phytother, 149(1999):P. 3.
  45. Jarr H., Leonardt S., Wunke W. «Agnus kastus als dopaminerges. Wirkprinzip in Mastodynon.» N. Ztsehr. Phytother, 12(1991):77-82.
  46. Sliutz G., Speiser P., Schultz A.M. «Agnus kastus extraks ingibit prolactin secrecion of pituitery cell.» Horm. Metabol. Res, 25(1993):243-255.
  47. Spengler B., Schmidt J., Porcel A. «Ilolation and characterization of cyclic diterpenes from BNO 1095 (Vitex agnus kastus).» In preparation (1999).
  48. Wunke W., Gorcow C., Jarry H. «Dopaminergie compounds in Vitex agnus kastus. Loew D., Rietbrock N. (Hrsg). Phytopharmaka in forschung und klinischer Anwendung.» Darmstadt: Steinkopf (1995):81-91.



How to Cite

Тихомиров, А. Л., & Леденкова, А. А. (2014). Mastodynia elimination at hormonal treatment of patients with uterine myoma. REPRODUCTIVE ENDOCRINOLOGY, (19), 86–90.



Tumors and pretumoral pathology

Most read articles by the same author(s)